Recruitment

Recruitment Status
Completed

Inclusion Criteria

patients who participated in MabThera study WA17042, and completed to at least the Week 24 visit;
eligible for re-treatment, based on clinical symptoms;
adult patients 18-80 years of age with active RA;
...
patients who participated in MabThera study WA17042, and completed to at least the Week 24 visit;
eligible for re-treatment, based on clinical symptoms;
adult patients 18-80 years of age with active RA;
patients of reproductive potential must be using reliable contraceptive methods.

Exclusion Criteria

development of any new contraindications to receiving MabThera;
women who are pregnant or breast-feeding.
current treatment with any other disease-modifying antirheumatic drug (apart from methotrexate), or any anti-TNFalfa, anti-IL1, or other biologic therapies;
...
development of any new contraindications to receiving MabThera;
women who are pregnant or breast-feeding.
current treatment with any other disease-modifying antirheumatic drug (apart from methotrexate), or any anti-TNFalfa, anti-IL1, or other biologic therapies;
patients who participated in MabThera study WA17042 but withdrew into the safety follow-up;

Summary

Conditions
Rheumatoid Arthritis
Type
Interventional
Phase
Phase 3
Design
  • Allocation: N/A
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 80 years
Gender
Both males and females

Inclusion Criteria

patients who participated in MabThera study WA17042, and completed to at least the Week 24 visit;
eligible for re-treatment, based on clinical symptoms;
adult patients 18-80 years of age with active RA;
...
patients who participated in MabThera study WA17042, and completed to at least the Week 24 visit;
eligible for re-treatment, based on clinical symptoms;
adult patients 18-80 years of age with active RA;
patients of reproductive potential must be using reliable contraceptive methods.

Exclusion Criteria

development of any new contraindications to receiving MabThera;
women who are pregnant or breast-feeding.
current treatment with any other disease-modifying antirheumatic drug (apart from methotrexate), or any anti-TNFalfa, anti-IL1, or other biologic therapies;
...
development of any new contraindications to receiving MabThera;
women who are pregnant or breast-feeding.
current treatment with any other disease-modifying antirheumatic drug (apart from methotrexate), or any anti-TNFalfa, anti-IL1, or other biologic therapies;
patients who participated in MabThera study WA17042 but withdrew into the safety follow-up;

Locations

Haifa, 3339419
Amsterdam, 1105 AZ
Manchester, M41 5SL
Würzburg, 97080
Indianapolis, Indiana, 46202-5149
...
Haifa, 3339419
Amsterdam, 1105 AZ
Manchester, M41 5SL
Würzburg, 97080
Indianapolis, Indiana, 46202-5149
Dublin, 4
Drammen, 3004
Tromsø, 9038
Jerusalem, 9112001
Seattle, Washington, 98104
Indianapolis, Indiana, 46260
Dallas, Texas, 75231
Oklahoma City, Oklahoma, 73109
Bruxelles, 1200
Ramat Gan, 5262000
Gent, 9000
Salt Lake City, Utah, 84132
Orlando, Florida, 32806
Calgary, Alberta, T2N 4Z6
Ratingen, 40882
Santa Maria, California, 93454
Chicago, Illinois, 60612
Mesa, Arizona, 85208
Tel Aviv, 6423906
Burlington, Vermont, 05401
Spokane, Washington, 99204
Delray Beach, Florida, 33484
Tulsa, Oklahoma, 74135
Jupiter, Florida, 33458
Los Angeles, California, 90045
Bois Guillaume, 76233
St Louis, Missouri, 63110
Philadelphia, Pennsylvania, 19141
Dallas, Texas, 75246
Philadelphia, Pennsylvania, 19152
Chapel Hill, North Carolina, 27599-7600
Toulouse, 31059
Kalamazoo, Michigan, 49048
Le Kremlin Bicetre, 94275
Los Angeles, California, 90048
Lansing, Michigan, 48910
Amarillo, Texas, 79124
Houston, Texas, 77074
Philadelphia, Pennsylvania, 19140
Bruxelles, 1070
Newcastle Upon Tyne, NE1 4LP
Smithtown, New York, 11787
Toronto, Ontario, M4N 3M5
Dayton, Ohio, 45402
Albany, New York, 12206
Tucson, Arizona, 85724
Fort Lauderdale, Florida, 33334
New York, New York, 10003
Pisa, Toscana, 56100
Shreverport, Louisiana, 71103
London, E11 1NR
Edmonton, Alberta, T6G 2S2
Boise, Idaho, 83702
Boston, Massachusetts, 02215
Duncansville, Pennsylvania, 16635
Paris, 75679
Chicago, Illinois, 60637
Manhasset, New York, 11030
Rochester, New York, 14618
Oslo, 0370
Haifa, 3109601
Leipzig, 04103
Boca Raton, Florida, 33486
Paradise Valley, Arizona, 85253
Berlin, 10117
Fullerton, California, 92835
Saint Louis, Missouri, 63141
Udine, Friuli-Venezia Giulia, 33100
Dresden, 01067
Cincinnati, Ohio, 45267-0563
Rochester, Minnesota, 55905
Oklahoma City, Oklahoma, 73103
Danbury, Connecticut, 06810
Mayfield, Ohio, 44143
Cork
Rancho Mirage, California, 92270
Hamilton, Ontario, L8N 2B6
Meridian, Idaho, 83642
Leeds, LS7 4SA
Waco, Texas, 76710
Seattle, Washington, 98101
Coeur D'alene, Idaho, 83814
Montpellier, 34295
Petach Tikva, 4941492
Greenville, North Carolina, 27834
Cannock, WS11 5XY
London, Ontario, N6A 4V2
Baltimore, Maryland, 21224
Pasadena, California, 91105
Madison, Wisconsin, 53792
Brescia, Lombardia, 25123
Little Rock, Arkansas, 72205

Tracking Information

NCT #
NCT02097745
Collaborators
Biogen
Investigators
Study Chair: Clinical Trials Hoffmann-La Roche